GE Healthcare has received clearance from FDA for its next-generation volume PET/CT application to help clinicians diagnose, stage, treat and monitor tumours and other lesions in the body. The FDA clearance includes a GE-patented Interactive Data Analysis (IDA) tool, which allows physicians to systematically track treatment over time and quantitatively interpret a patient's response to therapy.
The new IDA capability facilitates informed, objective treatment decision-making by automating several previously manual processes and presenting data in an organised, user-configurable format. PET VCAR offers several innovative workflow enhancements for both single- and multi-exam review, including exam-to-exam auto-registration, tumour segmentation and quantification, and multi-planar image review.
"PET VCAR is a full-body treatment, response and management tool for PET/CT imaging, which supports objective clinical decision-making by providing logical quantitative data, ultimately leading to accurate and personalised treatment," said Dr Kelly Piacsek, global oncology product manager for GE Healthcare. "The Interactive Data Analysis feature provides a tumour report card allowing physicians to systematically visualise, analyse and manage tumours over time with unparalleled efficiency. We believe PET VCAR will help improve the clinicians' daily reading experience and patient management."
|
